Aurinia Pharmaceuticals

(NASDAQ) AUPH

Current Price$15.34

Market Cap$2.05B

Since IPO (2012)+679%

5 Year+42%

1 Year+76%

1 Month-1%

Aurinia Pharmaceuticals last closing stock price
Metric	Price	Date
Last close	USD 15.96	2026-07-17

Aurinia Pharmaceuticals stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+1.14%	USD 15.78	2026-07-10
1 month	-1.12%	USD 16.14	2026-06-17
3 month	-0.56%	USD 16.05	2026-04-17
Year to date	+0.06%	USD 15.95	2025-12-31
1 year	+75.96%	USD 9.07	2025-07-17
3 year	+39.02%	USD 11.48	2023-07-18
5 year	+41.87%	USD 11.25	2021-07-16
Since inception	+678.54%	USD 2.05	2012-08-27

Aurinia Pharmaceuticals Financials at a Glance

Market Cap

$2.05B

Revenue (TTM)

$298.30M

Net Income (TTM)

$298.21M

EPS (TTM)

$2.16

P/E Ratio

7.38

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Price

$15.34

Volume

16,199

Open

$15.98

Price

$15.34

Volume

16,199

Open

$15.98

Previous Close

$15.96

Daily Range

$15.28 - $16.08

52-Week Range

$8.55 - $19.25

Estimated Earnings Date

Jul 30, 2026

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Price

$15.34

Volume

16,199

Open

$15.98

Previous Close

$15.96

Daily Range

$15.28 - $16.08

52-Week Range

$8.55 - $19.25

Estimated Earnings Date

Jul 30, 2026

AUPH News

Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million

Cory RenauerJun 7, 2026

Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?

Jonathan PoncianoDec 2, 2025

Page 1

AUPH: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aurinia Pharmaceuticals

Aurinia helps people manage diseases where the body attacks its own organs. Its main drug treats adults with kidney problems caused by lupus. The company sells these treatments in several countries around the world.

Treating the Body's Own Attacks

LUPKYNIS: Oral medicine used to treat adults with kidney inflammation caused by lupus; generated $73.6 million in net product sales in Q1 2026.
Aritinercept: Experimental drug in development to treat various autoimmune diseases by blocking specific proteins in the body.
Support Services: Manufacturing and development work for partners like Otsuka Pharmaceutical Co., Ltd.; generated $4.1 million in revenue in Q1 2026.

Strategic Growth and New Partners

Signed a deal in March 2026 to acquire Kezar Life Sciences, Inc. to add new autoimmune and cancer treatments to its pipeline.
Increased its share repurchase program by an additional $150 million in July 2025 to return value to shareholders.
Collaborated with Otsuka Pharmaceutical Co., Ltd. in December 2020 to develop and sell its main medicine in Europe and Japan.

Why the Monoplant Matters

The company operates a dedicated manufacturing facility called a Monoplant to produce its own medicine. This specialized site helps lower production costs and ensures a steady supply of drugs for patients worldwide.

What is Fueling the Growth?

Total revenue reached $77.7 million in Q1 2026, up 24.4% from the same period in 2025.
Operating income climbed to $41.4 million in Q1 2026, an 89.6% increase compared to the previous year.
Free cash flow rose to $32.5 million in Q1 2026, up from $1.3 million in Q1 2025.
Market capitalization reached $2 billion in Q1 2026, representing a 75.6% increase over the prior year.

Evolution of the Business

Aurinia has transitioned from a research firm into a profitable commercial business with growing product sales. Recent leadership changes and strategic acquisitions signal a focus on expanding its reach in the autoimmune disease market.

AI Generated • May 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

128

CEO

Kevin C. Tang

Website

www.auriniapharma.com

Headquarters

Edmonton, AB V8Z 7X8, CA

AUPH Financials

Key Financial Metrics (TTM)

Gross Margin

89.74%

Operating Margin

41.73%

Net Income Margin

99.97%

Return on Equity

64.48%

Return on Capital

15.99%

Return on Assets

41.19%

Earnings Yield

13.55%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.05B

Shares Outstanding

128.60M

Volume

16.20K

Avg. Volume

1.50M

Financials (TTM)

Gross Profit

$267.70M

Operating Income

$124.49M

EBITDA

$161.79M

Operating Cash Flow

$165.82M

Capital Expenditure

-$271.76K

Free Cash Flow

$165.55M

Cash & ST Invst.

$378.78M

Total Debt

$68.64M

Aurinia Pharmaceuticals Performance Analysis

Aurinia Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 134,030,000	193.9%
2023	2023-12-31	USD 175,513,000	31.0%
2024	2024-12-31	USD 235,133,000	34.0%
2025	2025-12-31	USD 283,055,000	20.4%

Aurinia Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	12.1%
Q3	2025-09-30	4.9%
Q4	2025-12-31	5.0%
Q1	2026-03-31	0.8%

Aurinia Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.76	-45.5%
2023	2023-12-31	USD -0.54	-28.5%
2024	2024-12-31	USD 0.04	N/A
2025	2025-12-31	USD 2.07	5169.0%

Aurinia Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-6.3%
Q3	2025-09-30	53.3%
Q4	2025-12-31	565.2%
Q1	2026-03-31	-83.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$77.71M

+24.4%

Gross Profit

$71.20M

+32.1%

Gross Margin

91.63%

N/A

Market Cap

$2.05B

N/A

Market Cap/Employee

$16.04M

N/A

Employees

128

N/A

Net Income

$34.36M

+47.2%

EBITDA

$49.75M

+64.4%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$378.78M

+21.1%

Total Debt

$68.64M

-11.9%

Accounts Receivable

$49.18M

+21.9%

Inventory

$46.41M

+0.5%

Long Term Debt

$50.50M

-19.0%

Short Term Debt

$18.14M

+16.7%

Return on Assets

41.19%

N/A

Return on Invested Capital

19.53%

N/A

Free Cash Flow

$32.52M

+2434.8%

Operating Cash Flow

$32.56M

+2404.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

HRMYHarmony Biosciences Holdings, Inc.

HRMYHarmony Biosciences Holdings, Inc.$33.63-0.41%

NUVBNuvation Bio Inc.

NUVBNuvation Bio Inc.$6.34+9.22%

ABCLAbCellera Biologics Inc.

ABCLAbCellera Biologics Inc.$5.96-7.89%

STOKStoke Therapeutics, Inc.

STOKStoke Therapeutics, Inc.$28.02-3.55%

CLDXCelldex Therapeutics, Inc.

CLDXCelldex Therapeutics, Inc.$35.63+0.78%

IMCRImmunocore Holdings plc

IMCRImmunocore Holdings plc$34.11-2.43%

BHVNBiohaven Ltd.

BHVNBiohaven Ltd.$14.96-3.11%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$98.61+0.04%

HLHecla Mining

HLHecla Mining$14.38+0.00%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$10.94-0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$68.98+0.02%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$41.92-0.02%

ADVBAdvanced Biomed

ADVBAdvanced Biomed$7.48+0.49%

TET1 Energy Inc.

TET1 Energy Inc.$6.01+0.03%

Questions About AUPH

What is the current price of Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals is trading at $15.34 per share.

What is the 52-week range for Aurinia Pharmaceuticals?

Over the past 52 weeks, Aurinia Pharmaceuticals has traded between $8.55 and $19.25.

How much debt does Aurinia Pharmaceuticals have?

As of the most recent reporting period, Aurinia Pharmaceuticals reported total debt of $68.64M.

How much cash does Aurinia Pharmaceuticals have on hand?

Aurinia Pharmaceuticals reported $41.01M in cash and cash equivalents in its most recent financial results.

What is Aurinia Pharmaceuticals’s dividend yield?

Aurinia Pharmaceuticals does not currently have a dividend yield.

Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Financials at a Glance

AUPH News

Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million

Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?

Aurinia (AUPH) Q2 Revenue Jumps 22%

Why Aurinia Pharmaceuticals Stock Is Slumping Today

Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday

Why Aurinia Pharmaceuticals Stock Is Glowing Green Today

Why Shares of Aurinia Pharmaceuticals Soared This Week

Why Aurinia Pharmaceuticals Stock Briefly Spiked Today

AUPH: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Aurinia Pharmaceuticals

Treating the Body's Own Attacks

Strategic Growth and New Partners

Why the Monoplant Matters

What is Fueling the Growth?

Evolution of the Business

AUPH Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Aurinia Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About AUPH

What is the current price of Aurinia Pharmaceuticals?

What is the 52-week range for Aurinia Pharmaceuticals?

How much debt does Aurinia Pharmaceuticals have?

How much cash does Aurinia Pharmaceuticals have on hand?

What is Aurinia Pharmaceuticals’s dividend yield?

Premium Investing Services